Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$28.82M+68.5%
Insmed logo
InsmedINSM
$6.26M+79.6%
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+1.1%
Enterprise value$1.4B-3.9%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335003
Line itemFor the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Cash flows from investing activities:
Purchase of investments(351,045)(45,084)
Maturity and sales of investments126,919109,384
Purchase of property and equipment(2,636)(75,447)
Purchase of intangible assets(1,000)(2,000)
Acquisition of strategic investment(245,819)
Net cash used in investing activities(227,762)(258,966)
Cash flows from financing activities:

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s payments to acquire property, plant, and equipment?
Sarepta Therapeutics, Inc. (SRPT) reported payments to acquire property, plant, and equipment of $555K in Q2 2026.
How has Sarepta Therapeutics, Inc.'s payments to acquire property, plant, and equipment changed year-over-year?
Sarepta Therapeutics, Inc.'s payments to acquire property, plant, and equipment decreased by 98.3% year-over-year, from $31.8M to $555K.
What is the long-term trend for Sarepta Therapeutics, Inc.'s payments to acquire property, plant, and equipment?
Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s payments to acquire property, plant, and equipment has grown at a 27.6% compound annual growth rate (CAGR), from $38.49M to $101.97M.
What does payments to acquire property, plant, and equipment mean?
Payments to Acquire Property, Plant, and Equipment

Ask your AI about Sarepta Therapeutics, Inc.'s payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude